Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, K S M, Contractor, R, Haass, N K, Lee, J T, Nathanson, K L, Medina, C A, Flaherty, K T, Herlyn, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360037/
https://www.ncbi.nlm.nih.gov/pubmed/17245336
http://dx.doi.org/10.1038/sj.bjc.6603596
_version_ 1782152948641431552
author Smalley, K S M
Contractor, R
Haass, N K
Lee, J T
Nathanson, K L
Medina, C A
Flaherty, K T
Herlyn, M
author_facet Smalley, K S M
Contractor, R
Haass, N K
Lee, J T
Nathanson, K L
Medina, C A
Flaherty, K T
Herlyn, M
author_sort Smalley, K S M
collection PubMed
description The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
format Text
id pubmed-2360037
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23600372009-09-10 Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels Smalley, K S M Contractor, R Haass, N K Lee, J T Nathanson, K L Medina, C A Flaherty, K T Herlyn, M Br J Cancer Translational Therapeutics The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies. Nature Publishing Group 2007-02-12 2007-01-23 /pmc/articles/PMC2360037/ /pubmed/17245336 http://dx.doi.org/10.1038/sj.bjc.6603596 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Smalley, K S M
Contractor, R
Haass, N K
Lee, J T
Nathanson, K L
Medina, C A
Flaherty, K T
Herlyn, M
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title_full Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title_fullStr Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title_full_unstemmed Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title_short Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
title_sort ki67 expression levels are a better marker of reduced melanoma growth following mek inhibitor treatment than phospho-erk levels
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360037/
https://www.ncbi.nlm.nih.gov/pubmed/17245336
http://dx.doi.org/10.1038/sj.bjc.6603596
work_keys_str_mv AT smalleyksm ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT contractorr ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT haassnk ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT leejt ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT nathansonkl ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT medinaca ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT flahertykt ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels
AT herlynm ki67expressionlevelsareabettermarkerofreducedmelanomagrowthfollowingmekinhibitortreatmentthanphosphoerklevels

Ejemplares similares